ClinicalTrials.Veeva

Menu

Maternal & Offspring Microbiome Study (MOMS)

Stanford University logo

Stanford University

Status

Active, not recruiting

Conditions

Inflammation
Pregnancy Related
Microbiome
Immune Function

Treatments

Behavioral: Fiber
Behavioral: Fermented Foods

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of the study is to learn how different dietary interventions affect microbiota diversity in pregnant women and the transmission of microbiota to their infants during pregnancy, birth, and postpartum.

Full description

This research study aims to understand the relationship of dietary fiber, fermented foods, and the microbiome, specifically during pregnancy and postpartum. The investigators know that the composition of the microbiome can have an important effect on overall health, and a greater variety will confer more health benefits. Research suggests that maternal microbiota play an important role in the development of their offspring's microbiota during pregnancy, childbirth, and breastfeeding. The purpose of this study is to assess how diet impacts maternal microbiome during pregnancy and their infant's microbiome up to about two years postpartum.

Potential pregnant participants will be recruited during their first trimester up to 22 weeks. After completion of the baseline visit and sample collection, they will be randomized to start a diet high in fiber, high in fermented foods, high in both fiber and fermented foods, or a usual care group. Participants will be asked to provide blood, stool, vaginal swab, and breast milk samples periodically throughout the study. Cord blood will be collected after childbirth, and infant blood from a heel stick will be collected twice. They will also be asked to fill out online questionnaires and perform dietary recalls with study diet assessors.

After completing the study, participants will be invited to continue to participate in an extension of the study for approximately three and a half additional years. The purpose of this extension is to continue to assess how diet impacts the mother's microbiome postpartum and the child's microbiome up to about 5 years of age.

Enrollment

135 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • > 18 years of age
  • Singleton pregnancies
  • Recruit during the first trimester and up to 22 weeks of pregnancy.
  • Healthy subjects willing and able to provide blood, stool, vaginal swab, and breast milk samples.
  • Must be able to provide signed and dated informed consent.

Exclusion criteria

  • Pre-pregnancy BMI greater than 40
  • Blood pressure SBP: > 160 mmHg -OR- DBP: > 90 mmHg
  • Kidney disease
  • Liver disease
  • Anemia
  • Symptomatic gallstones
  • History of bariatric surgery
  • Acute disease at time of enrollment (i.e. flu or gastroenteritis). May delay sampling until subject recovers.
  • Chronic, clinically significant, unstable (unresolved, requiring on-going changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history
  • History of active uncontrolled gastrointestinal disorders or diseases including:
  • Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
  • Irritable bowel syndrome (IBS) (moderate-severe);
  • Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated)
  • Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection.
  • Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • Confirmed or suspected autoimmune disease

Medications:

  • Weight loss medications
  • Regular high dose aspirin
  • Regular use of prescription opiate pain medication

If taken in the past 2 months:

  • Systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular or oral)
  • Corticosteroids (intravenous, intramuscular, oral, nasal or inhaled)
  • Cytokines
  • Methotrexate or immunosuppressive cytotoxic agents

Diet & Lifestyle:

  • Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or > 14 drinks/week.
  • Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products

Maternal chronic medical conditions:

  • Pre-gestational diabetes (T1 or T2)
  • History of gestational diabetes
  • On medication that is an immune modulators or chronic steroid use
  • Hyperemesis gravidarum

Pregnancy history:

  • Preterm birth
  • Recurrent pregnancy loss

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

135 participants in 4 patient groups

Fiber
Experimental group
Description:
Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.
Treatment:
Behavioral: Fiber
Fermented Foods
Experimental group
Description:
Participants will be asked to consume 6 servings of fermented foods per day.
Treatment:
Behavioral: Fermented Foods
Fiber + Fermented Foods
Experimental group
Description:
Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.
Treatment:
Behavioral: Fermented Foods
Behavioral: Fiber
Comparator
No Intervention group
Description:
Participants will receive usual care for pregnancy and postpartum.

Trial contacts and locations

1

Loading...

Central trial contact

Tayler Hennings, MPH; Jennifer Robinson, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems